DEALS: Gilead Sciences acquires Myogen for $2.5B


Gilead Sciences acquires Myogen for $2.5B


DEALS

WHO

WITH

WHAT

SCOOP

Gilead Sciences

Myogen

$2.5B buyout

Gilead Sciences announced that it will acquire Myogen for $2.5 billion in a move designed to bolster Gilead's pulmonary program.

Sigma Pharmaceuticals

Australian Pharmaceutical Industries

$422M buyout

The buyout bid would create a company that controls two thirds of the Australian market.

Genentech

CGI Pharmaceuticals

$525M development deal

Genentech has agreed to pay CGI Pharmaceuticals $25 million up front and up to $500 million in milestones for the rights to collaborate on the development and commercialization of therapeutics for an unidentified target for the treatment of multiple cancer and autoimmune indications.

Biogen Idec

UCB

$200M development pact

Biogen Idec and Belgium-based UCB have signed a pact to develop UCB's CDP323, a small molecule alpha4-integrin inhibitor being developed as a treatment for multiple sclerosis.

Plexxikon

Servier

$100M collaboration deal

Plexxikon and France's Servier have struck a collaboration deal to discover non-peptidic renin inhibitors.

Wyeth

Biotica Technology

$195M licensing deal

Wyeth gains rights to Biotica's advanced drug candidates, a portfolio of additional rapamycin analogs, and the technology to discover new compounds.

Takeda

Xenon Pharmaceuticals

$75.5 licensing deal

Canada's Xenon Pharmaceuticals has agreed to license out the rights to its lead product for pain, XEN401, for Japan and certain Asian markets to Takeda.

Roche

Plexxikon

$40M deal

Roche and Plexxikon have signed a deal to develop and commercialize PLX4032, a therapy for cancer that selectively inhibits B-Raf(V600E).

Pfizer

PowderMed

Development deal

Pfizer has struck a deal to buy the UK's PowderMed, a company that has been developing a new generation of DNA-based vaccines.

Starpharma

Dendritic

Acquisition

Starpharma has struck a deal to buy all the stock of Dendritic Nanotechnologies it doesn't already own for about $7 million in Starpharma shares.

Barr Pharmaceuticals

Pliva

Acquisition

Barr Pharmaceuticals announced that it has acquired more than 70 percent of Pliva's stock.

Valentis

Urigen

Merger

Burlingame, CA-based Valentis announced that it would merge with Urigen through a stock swap.

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.